| Molecular imaging of hypoxia with radiolabelled agents G Mees, R Dierckx, C Vangestel, C Van de Wiele European journal of nuclear medicine and molecular imaging 36, 1674-1686, 2009 | 246 | 2009 |
| Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors T Vandamme, M Beyens, KO de Beeck, F Dogan, PM van Koetsveld, ... British journal of cancer 114 (6), 650-658, 2016 | 87 | 2016 |
| Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators ES Moon, F Elvas, G Vliegen, S De Lombaerde, C Vangestel, ... EJNMMI radiopharmacy and chemistry 5, 1-20, 2020 | 73 | 2020 |
| ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice A Kurdi, M Cleenewerck, C Vangestel, S Lyssens, W Declercq, ... Biochemical pharmacology 138, 150-162, 2017 | 68 | 2017 |
| 99mTc-(CO) 3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab C Vangestel, C Van de Wiele, N Van Damme, S Staelens, P Pauwels, ... Journal of Nuclear Medicine 52 (11), 1786-1794, 2011 | 53 | 2011 |
| Characterization of [99mTc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis F Elvas, C Vangestel, S Rapic, J Verhaeghe, B Gray, K Pak, S Stroobants, ... Molecular imaging and biology 17, 838-847, 2015 | 49 | 2015 |
| In vivo imaging of apoptosis in oncology: an update C Vangestel, M Peeters, G Mees, R Oltenfreiter, HH Boersma, PH Elsinga, ... Molecular imaging 10 (5), 7290.2010. 00058, 2011 | 48 | 2011 |
| Development of a novel antibody–tetrazine conjugate for bioorthogonal pretargeting A Maggi, E Ruivo, J Fissers, C Vangestel, S Chatterjee, J Joossens, ... Organic & biomolecular chemistry 14 (31), 7544-7551, 2016 | 46 | 2016 |
| 99mTc-Duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET F Elvas, J Boddaert, C Vangestel, K Pak, B Gray, S Kumar-Singh, ... Journal of Nuclear Medicine 58 (4), 665-670, 2017 | 43 | 2017 |
| Development of antibody immuno-PET/SPECT radiopharmaceuticals for imaging of oncological disorders—an update J Dewulf, K Adhikari, C Vangestel, TVD Wyngaert, F Elvas Cancers 12 (7), 1868, 2020 | 37 | 2020 |
| Forcing cancer cells to commit suicide C Vangestel, C Van de Wiele, G Mees, M Peeters Cancer Biotherapy and Radiopharmaceuticals 24 (4), 395-407, 2009 | 37 | 2009 |
| Early prediction of tumor response to treatment: preclinical validation of 99mTc-duramycin F Elvas, C Vangestel, K Pak, P Vermeulen, B Gray, S Stroobants, ... Journal of Nuclear Medicine 57 (5), 805-811, 2016 | 34 | 2016 |
| Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal … C Vangestel, C Van de Wiele, G Mees, K Mertens, S Staelens, ... Molecular imaging 11 (2), 7290.2011. 00034, 2012 | 33 | 2012 |
| Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator T Van Den Broeck, F Stevenaert, S Taveirne, V Debacker, C Vangestel, ... Blood, The Journal of the American Society of Hematology 112 (13), 5046-5051, 2008 | 30 | 2008 |
| Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology S Rapic, C Vangestel, F Elvas, J Verhaeghe, TV den Wyngaert, L Wyffels, ... Molecular Imaging and Biology 19, 560-569, 2017 | 25 | 2017 |
| Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F] fluoro-D-glucose uptake? G Mees, R Dierckx, C Vangestel, D Laukens, N Van Damme, ... Molecular imaging 12 (1), 49-58, 2013 | 25 | 2013 |
| FDG uptake in primary squamous cell carcinoma of the head and neck P Deron, C Vangestel, I Goethals, A De Potter, M Peeters, H Vermeersch, ... Nuklearmedizin-NuclearMedicine 50 (01), 15-21, 2011 | 25 | 2011 |
| 18F-Flortanidazole hypoxia PET holds promise as a prognostic and predictive imaging biomarker in a lung cancer xenograft model treated with metformin and radiotherapy S De Bruycker, C Vangestel, T Van den Wyngaert, P Pauwels, S Staelens, ... Journal of Nuclear Medicine 60 (1), 34-40, 2019 | 24 | 2019 |
| In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells C Vangestel, M Peeters, R Oltenfreiter, Y D'Asseler, S Staelens, ... Nuclear medicine and biology 37 (8), 965-975, 2010 | 23 | 2010 |
| Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using 18F-FDG PET/CT for Monitoring Treatment Response R Capistrano, C Vangestel, A Wouters, Y Dockx, P Pauwels, S Stroobants, ... Cancer Biotherapy and Radiopharmaceuticals 31 (3), 99-109, 2016 | 22 | 2016 |
Sigrid StroobantsVerified email at uantwerpen.be
